On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experienceSudipta Chakraborty, Ashutosh Dash, K.V. Vimalnath et al.|Journal of Radioanalytical and Nuclear Chemistry|2014Cited by 51
Radiolanthanide-loaded agglomerated Fe <sub>3</sub> O <sub>4</sub> nanoparticles for possible use in the treatment of arthritis: formulation, characterization and evaluation in ratsSudipta Chakraborty, Ashutosh Dash, K. Sharma et al.|Journal of Materials Chemistry B|2015Cited by 29
Preparation, evaluation, and first clinical use of <sup>177</sup>Lu‐labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacySudipta Chakraborty, Ashutosh Dash, K.V. Vimalnath et al.|Journal of Labelled Compounds and Radiopharmaceuticals|2014Cited by 28
Prospects of medium specific activity <sup>177</sup>Lu in targeted therapy of prostate cancer using <sup>177</sup>Lu‐labeled PSMA inhibitorSudipta Chakraborty, Ashutosh Dash, Rubel Chakravarty et al.|Journal of Labelled Compounds and Radiopharmaceuticals|2016Cited by 27
Radiochemistry, pre-clinical studies and first clinical investigation of 90 Y-labeled hydroxyapatite (HA) particles prepared utilizing 90 Y produced by (n,γ) routeK.V. Vimalnath, Ashutosh Dash, Sudipta Chakraborty et al.|Nuclear Medicine and Biology|2015Cited by 25